Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2021.830164 Endocrinology Erratum Erratum: Follow Your Nose: A Key Clue to Understanding and Treating COVID-19 Frontiers Production Office * Frontiers Media SA, Lausanne, Switzerland

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology

 16 12 2021 2021 12 830164 06 12 2021 06 12 2021 Copyright © 2021 Frontiers Production Office 2021 Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An Erratum on Follow Your Nose: A Key Clue to Understanding and Treating COVID-19 by Edwards, C., Klekot, O., Halugan, L. and Korchev, Y. (2021). Front. Endocrinol. 12:747744. doi: 10.3389/fendo.2021.747744 COVID-19 mineralocorticoid receptor spironolactone and dexamethasone ATP - adenosine triphosphate anosmia and ageusia

Owing to a production error, several dependent variables were omitted from the part of Table 2 that pertains to Study 1 in the article as originally published. The variables in question are mean diastolic blood pressure, breath rate, C-reactive protein concentration, D-dimer concentration, fasting glucose concentration and plasma potassium concentration. The complete part of Table 2 that pertains to Study 1 is presented here.

Study 1. Repeated measures analysis comparing changes in variables from baseline to 5 days treatment (T1).

Dependent variable Treatment group  Mean baseline Mean T1 p-value of comparison baseline vs T1 p-value of T1 comparison of Group II vs Group I
Loss of smell/taste, n I 33 (82.5) 30 (75) NS <0.05
II 34 (85) 19 (47.5) <0.05
Dyspnea, n I 30 (75) 10 (25) <0.001 NS
II 28 (70) 8 (20) <0.001
Dry cough, n I 36 (90) 18 (45) <0.001 NS
II 32 (80) 12 (30) <0.001
Fever, n I 38 (95) 10 (25) <0.001 NS
II 37 (92.5) 4 (10) <0.001
Need for oxygen, n I 22 (55) 7 (17.5) NS NS
II 18 (45) 5 (12.5) NS
BP syst., mm Hg I 130.6 ± 10.5 165.1 ± 12.1 <0.05 <0.05
II 137.5 ± 22.5 128.3 ± 12.0 NS
BP diast., mm Hg I 86.0 ± 8.6 89.0 ± 10.6 NS NS
II 85.25 ± 12.4 81.1 ± 6.7 NS
Breath rate/min I 24.8 ± 4.6 18.4 ± 3.1 NS NS
II 24.2 ± 3.1 16.2 ± 1.8 <0.05
CRP, mg/l I 72.4 ± 16.7 28.1 ± 12.9 <0.05 NS
II 65.8 ± 17.9 17.1 ± 8.7 <0.05
D-dimer, ng/ml I 736.7 ± 112.6 574.8 ± 106.4 NS <0.05
II 755.5 ± 106.1 357.3 ± 71.1 <0.001
Fasting glucose, mmol/l I 5.9 ± 1.5 12.69 ± 1.31 <0.05 <0.05
II 6.9 ± 2.2 8.44 ± 1.60 NS
[K+] plasma, mmol/l I 4.36 ± 0.32 4.28 ± 0.50 NS NS
II 4.22 ± 0.40 4.43 ± 0.45 NS

SD, standard deviation; mean BP, mean blood pressure; [K+] plasma, plasma concentration of potassium; CRP, C-reactive protein. Figures are expressed as Mean and Standard Deviation. NS, non-significant difference. No patient required ventilation: patients with oxygen saturation less than 92% given oxygen by mask.

The publisher apologizes for this error. The original article has been updated.